What is the scientific and clinical rationale? Triple therapy in COPD patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021
Anti-IgE therapy: current knowledge and future perspective Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019
Antiviral therapy – the evidence base and clinical trials Source: International Congress 2015 – PG11 Emerging infectious diseases and pandemic planning Year: 2015
The search for evidence of the efficacy of augmentation therapy in AATD Source: Annual Congress 2013 –Alpha-1 antitrypsin deficiency and the lung: celebrating the 50th anniversary of its first description Year: 2013
Clinical effectiveness of triple therapy in the management of COPD: A systematic review Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD Year: 2010
Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001
At the interface: the translational science supporting the clinical use of anti-cytokine therapy Source: International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost? Year: 2018
The concept of control in COPD: a new proposal for optimising therapy Source: Eur Respir J 2014; 44: 1072-1075 Year: 2014
COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020
Evidence provided by recent meta-analyses on treatment: what is new? Source: Annual Congress 2012 - PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up (TB PAN-NET) Year: 2012
Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios Source: Eur Respir J 2015; 45: 25-29 Year: 2015
Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008
Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009
Looking back to go forward: adherence to inhaled therapy before biologic therapy in severe asthma Source: Eur Respir J, 55 (5) 2000954; 10.1183/13993003.00954-2020 Year: 2020